Results 71 to 80 of about 1,997 (174)

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Cost‐Effective Nanosensor Solutions for Ultra‐Sensitive Detection of Metronidazole

Analytical Science Advances, Volume 6, Issue 1, June 2025.
ABSTRACT Metronidazole (MNZ) is a widely used imidazole antibiotic effective against bacterial and protozoal infections, including giardiasis, trichomoniasis, bacterial vaginosis, and antibiotic‐associated colitis. However, prolonged and excessive use of MNZ can lead to serious side effects, such as peripheral neuropathies, toxicity, and optic ...
Ahmad Mobed, Mohammad Darvishi, Vahid Alivirdiloo, Sara Ebrahimi, Mobasher Hajiabbasi, Farhood Ghazi, Hamidreza Hassanzadeh Khanmiri   +6 more
wiley   +1 more source

LOMITAPIDE TREATMENT HIGHLY AFFECTS LIPOPROTEIN PROFILE AND HDL FUNCTIONALITY IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA [PDF]

, 2015
Aim: Lomitapide is a recently approved cholesterol lowering agent. Cholesterol Efflux Capacity (CEC), index of HDL functionality, was found impaired in FH patients.
Mulder, M., Verhoeven, A., FAVARI, Elda, Averna, M., J., Abcefalù, A. B. Cefalù, RONDA, Nicoletta, BERNINI, Franco, Sijbrands, E., Verhoven, A., Yahya, R., Lennep, J. Roeters van, ZIMETTI, Francesca, ADORNI, Maria Pia, Bos, S., Roeters van Lennep, Cefalù, A. B.   +16 more
core   +1 more source

Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia

, 2019
Introduction: Homozygous familial hypercholesterolaemia (HoFH) is a rare, autosomal disease affecting the clearance of low-density lipoprotein cholesterol (LDL-C) from circulation, and leading to early-onset atherosclerotic cardiovascular disease (ASCVD).
Masana, Luis, Sánchez Hernández, Rosa María, Bogsrud, Martin P., Hussein, Osamah, Novoa Mogollón, Francisco, Nóvoa, F. Javier, Sanchez-Hernández, Rosa M., Lund, Allan M., Ben-Omran, Tawfeg, Santos, Raul D., Ibarretxe, Daiana, Kolovou, Genovefa, Araujo, María, Ariceta, Gema   +13 more
core   +2 more sources

Hypolypidemic therapy in the XXI century: what is new?

RUDN Journal of Medicine
Relevance. The leading position in mortality throughout the world is occupied by cardiovascular diseases, caused be atherosclerosis process. Statins used to be the gold standard of lipid-lowering therapy for a long time due to their high efficacy ...
Natalya Yu. Ob’edkova, Diana N. Usacheva, Galina S. Mal, Evgenij G. Ob’edkov   +3 more
doaj   +1 more source

Depletion of Hepatic SREBP2 Protects Against Hypercholesterolemia and Atherosclerosis through the ANGPTL3‐LPL Axis

Advanced Science, Volume 12, Issue 18, May 15, 2025.
This study reveals a novel crosstalk between hepatic SREBP2‐mediated cholesterol biosynthesis pathway and peripheral lipoprotein lipase‐mediated lipolysis pathway in the regulation of systemic lipid metabolism. Notably, the lipid‐lowering effects of SREBP2 inhibition are independent of a functional LDL receptor, highlighting the potential of acute ...
Yifan Wang, Jia You Sarafina Choe, Yu Shi, Thi Tun Thi, Xiaoyun Cao, Yang Hu, Kai Yan Cheng, Hui Li, Yang Ji, Yan Liu, Matthew Ackers‐Johnson, Roger S.Y. Foo, Yujia Shen, Haojie Yu   +13 more
wiley   +1 more source

"Therapy with Lomitapide in Homozygous Familial Hypercholesterolemia"

, 2022
reservedBACKGROUND: l’ipercolesterolemia familiare omozigote (HoFH) è una patologia rara, pericolosa per la vita, caratterizzata da livelli molto elevati di colesterolo LDL e da malattia aterosclerotica cardiovascolare (ACVD) precoce e in rapida ...
TOSIN, PAOLA
core  

Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide [PDF]

, 2015
Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disease characterised by markedly elevated plasma levels of low-density lipoprotein-cholesterol (LDL-C).
Roeters van Lennep, Jeanine; id_orcid, AVERNA, Maurizio, Alonso, R., Roeters van Lennep, Jeanine, Averna, M, Alonso, R, Roeters Van Lennep, J.   +6 more
core   +1 more source

Lomitapide ed FH

, 2019
L'ipercolesterolemia familiare omozigote è una malattia rara, caratterizzata da elevatissimi livelli di LDL Col, responsabili di un'aterosclerosi accelerata, i cui primi eventi si verificano durante l'adolescenza.
gabriella iannuzzo
core  

Sustained LDL-C lowering and stable hepatic fat levels in patients with homozygous familial hypercholesterolemia treated with the Microsomal Triglyceride Transfer Protein Inhibitor, lomitapide: results of an ongoing long-term extension study

, 2013
BACKGROUND: Patients with Homozygous Familial Hypercholesterolemia (HoFH) are at very high risk for premature cardiovascular disease and are refractory to existing lipid lowering drug therapy.
Rader DJ, Meagher EA, Vigna GB, the HoFH lomitapide study investigators, Bloedon LAT, Blom DJ, Hegele RA, Cuchel M, du Toit Theron H, Averna MR, STEFANUTTI, Claudia, Sirtori CR, Gaudet D, Shah PK   +13 more
core